Metformin, an oral hypoglycemic agent, is commonly used in patients with type II diabetes mellitus. Studies have shown its use is associated with a reduction in major cardiovascular events (MACE) in patients with type 2 diabetes such as hospitalization for acute myocardial infarction, stroke, transient ischemic attack, or cardiovascular death. There is also a suggestion that metformin may have effects beyond those relating to lowering of blood sugar. The goal of this review is to assess the effects of metformin in coronary artery disease (CAD), but more importantly, its effects on disease states other than CAD.
de BhailísÁMAzmiSKalraPA. Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes. Ther Adv Endocrinol Metab2021; 12: 20420188211 020664.
2.
ForouhiNGWarehamNJ.Epidemiology of diabetes. Medicine (Abingdon)2014; 42(12): 698–702.
3.
NdisangJFVannacciARastogiS.Insulin resistance, type 1 and type 2 diabetes, and related complications 2017. J Diabetes Res2017; 2017(1): 1478294.
4.
SkylerJSBakrisGLBonifacioE, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes2017; 66(2): 241–255.
5.
ChenYHWangPHChenPN, et al. Molecular and cellular mechanisms of metformin in cervical cancer. Cancers (Basel)2021; 13(11): 2545.
6.
SirtoriCRFranceschiniGGalli-KienleM, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther1978; 24(6): 683–693.
7.
LiangXGiacominiKM.Transporters involved in metformin pharmacokinetics and treatment response. J Pharm Sci2017; 106(9): 2245–2250.
8.
BaileyCJ.Biguanides and NIDDM. Diabetes Care1992; 15(6): 755–772.
9.
ChomanicovaNGazovaAAdamickovaA, et al. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin. Physiol Res2021; 70(4): 501–508.
WuHZhangY.Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell2014; 156(1–2): 45–68.
12.
YanJBLaiCCJhuJW, et al. Insulin and metformin control cell proliferation by regulating TDG-mediated DNA demethylation in liver and breast cancer cells. Mol Ther Oncolytics2020; 18: 282–294.
13.
StumvollMNurjhanNPerrielloG, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med1995; 333(9): 550–554.
14.
McIntyreHDMaABirdDM, et al. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Aust N Z J Med1991; 21(5): 714–719.
15.
United Kingdom Prospective Diabetes Study (UKPDS). 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ1995; 310(6972): 83–88.
16.
WuMSJohnstonPSheuWH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care1990; 13(1): 1–8.
17.
GlueckCJFontaineRNWangP, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism2001; 50(7): 856–861.
18.
SalpeterSRBuckleyNSKahnJA, et al. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med2008; 121(2): 149–157.e2.
19.
FerranniniE.The target of metformin in type 2 diabetes. N Engl J Med2014; 371(16): 1547–1548.
20.
MadirajuAKErionDMRahimiY, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature2014; 510(7506): 542–546.
21.
HuMYePLiaoH, et al. Metformin protects H9C2 cardiomyocytes from high-glucose and hypoxia/reoxygenation injury via inhibition of reactive oxygen species generation and inflammatory responses: role of AMPK and JNK. J Diabetes Res2016; 2016(1): 2961954.
22.
LennickeCRahnJLichtenfelsR, et al. Hydrogen peroxide – production, fate and role in redox signaling of tumor cells. Cell Commun Signal2015; 13(1): 39.
23.
RheeSGChangT-SBaeYS, et al. Hydrogen peroxide as intracellular messenger. In: BhattacharyaJ (ed.) Cell signaling in vascular inflammation. Totowa, NJ: Humana Press; 2005, pp. 191–202.
24.
AlgireCMoiseevaODeschênes-SimardX, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila)2012; 5(4): 536–543.
25.
VialGDetailleDGuigasB.Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol (Lausanne)2019; 10: 294.
26.
WesselsBCiapaiteJvan den BroekNM, et al. Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent manner. PLoS One2014; 9(6): e100525.
27.
BridgesHRJonesAJPollakMN, et al. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J2014; 462(3): 475–487.
28.
AljofanMRiethmacherD.Anticancer activity of metformin: a systematic review of the literature. Future Sci OA2019; 5(8): Fso410.
29.
American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care2019; 42(Suppl 1): S90–S102.
30.
DaviesMJD’AlessioDAFradkinJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care2018; 41(12): 2669–2701.
31.
QaseemABarryMJHumphreyLL, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline update from the American College of Physicians. Ann Intern Med2017; 166(4): 279–290.
32.
DeFronzoRAGoodmanAM.Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med1995; 333(9): 541–549.
33.
RizzacasaBAmatiFRomeoF, et al. Epigenetic modification in coronary atherosclerosis: JACC review topic of the week. J Am Coll Cardiol2019; 74(10): 1352–1365.
34.
HanYXieHLiuY, et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol2019; 18(1): 96.
35.
HongJZhangYLaiS, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care2013; 36(5): 1304–1311.
36.
KooyAde JagerJLehertP, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med2009; 169(6): 616–625.
37.
MaruthurNMTsengEHutflessS, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med2016; 164(11): 740–751.
38.
RoumieCLChipmanJMinJY, et al. Association of treatment with metformin versus sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA2019; 322(12): 1167–1177.
39.
HolmanRRPaulSKBethelMA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med2008; 359(15): 1577–1589.
40.
AbualsuodARutlandJJWattsTE, et al. The effect of metformin use on left ventricular ejection fraction and mortality post-myocardial infarction. Cardiovasc Drugs Ther2015; 29(3): 265–275.
41.
DoreFJDominguesCCAhmadiN, et al. The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial. Cardiovasc Diabetol2018; 17(1): 65.
42.
SarduCPaolissoPSacraC, et al. Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: The CODYCE Multicenter Prospective Study. Diabetes Care2019; 42(10): 1946–1955.
43.
AneddaARialEGonzález-BarrosoMM.Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels. J Endocrinol2008; 199(1): 33–40.
44.
FaurePRossiniEWiernspergerN, et al. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes1999; 48(2): 353–357.
45.
IsodaKYoungJLZirlikA, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol2006; 26(3): 611–617.
46.
KahnSEHaffnerSMHeiseMA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med2006; 355(23): 2427–2443.
47.
MatherKJVermaSAndersonTJ.Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol2001; 37(5): 1344–1350.
48.
VitaleCMercuroGCornoldiA, et al. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med2005; 258(3): 250–256.
49.
ShinHSchneeweissSGlynnRJ, et al. Cardiovascular outcomes in patients initiating first-line treatment of type 2 diabetes with sodium-glucose cotransporter-2 inhibitors versus metformin: a cohort study. Ann Intern Med2022; 175(7): 927–937.
50.
DaviesMJWoolfNRowlesPM, et al. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J1988; 60(6): 459–464.
51.
SataMSaiuraAKunisatoA, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med2002; 8(4): 403–409.
52.
KockxMMDe MeyerGRMuhringJ, et al. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation1998; 97(23): 2307–2315.
53.
MarchioPGuerra-OjedaSVilaJM, et al. Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxid Med Cell Longev2019; 2019: 8563845.
54.
StojanovićSDFiedlerJBauersachsJ, et al. Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. Eur Heart J2020; 41(31): 2983–2996.
55.
WangDYangYLeiY, et al. Targeting foam cell formation in atherosclerosis: therapeutic potential of natural products. Pharmacol Rev2019; 71(4): 596–670.
56.
XuHJiangJChenW, et al. Vascular macrophages in atherosclerosis. J Immunol Res2019; 2019: 4354786.
57.
VasamsettiSBKarnewarSKanugulaAK, et al. Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes2015; 64(6): 2028–2041.
58.
MoluskyMMHsiehJLeeSX, et al. Metformin and AMP kinase activation increase expression of the sterol transporters ABCG5/8 (ATP-binding cassette transporter G5/G8) with potential antiatherogenic consequences. Arterioscler Thromb Vasc Biol2018; 38(7): 1493–1503.
59.
YuLLZhuMHuangY, et al. Metformin relieves acute respiratory distress syndrome by reducing miR-138 expression. Eur Rev Med Pharmacol Sci2018; 22(16): 5355–5363.
60.
SongJRenPZhangL, et al. Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4. Biochem Biophys Res Commun2010; 393(1): 89–94.
61.
TaniguchiNKawakamiYMaruyamaI, et al. HMGB proteins and arthritis. Hum Cell2018; 31(1): 1–9.
62.
WuHLiRPeiLG, et al. Emerging role of high mobility group box-1 in thrombosis-related diseases. Cell Physiol Biochem2018; 47(4): 1319–1337.
63.
BortolottoVGrilliM.Every cloud has a silver lining: proneurogenic effects of Aβ oligomers and HMGB-1 via activation of the RAGE-NF-κB axis. CNS Neurol Disord Drug Targets2017; 16(10): 1066–1079.
64.
PurcellIFPoole-WilsonPA.Heart failure: why and how to define it?Wiley Online Library; 1999, pp. 7–10.
65.
BraunwaldEBristowMR.Congestive heart failure: fifty years of progress. Circulation2000; 102(20 Suppl 4): Iv14–Iv23.
66.
AlgahimMFSenSTaegtmeyerH.Bariatric surgery to unload the stressed heart: a metabolic hypothesis. Am J Physiol Heart Circ Physiol2012; 302(8): H1539–H1545.
67.
LavieCJAlpertMAArenaR, et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail2013; 1(2): 93–102.
68.
DevereuxRBRomanMJParanicasM, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation2000; 101(19): 2271–2276.
69.
FactorSMBorczukACharronMJ, et al. Myocardial alterations in diabetes and hypertension. Diabetes Res Clin Pract1996; 31: S133–S142.
70.
RazeghiPYoungMECockrillTC, et al. Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation2002; 106(4): 407–411.
71.
SelvinEBolenSYehHC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med2008; 168(19): 2070–2080.
72.
KinsaraAJIsmailYM.Metformin in heart failure patients. Indian Heart J2018; 70(1): 175–176.
73.
PonikowskiPVoorsAAAnkerSD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail2016; 18(8): 891–975.
74.
KhanMSSolomonNDeVoreAD, et al. Clinical outcomes with metformin and sulfonylurea therapies among patients with heart failure and diabetes. JACC Heart Fail2022; 10(3): 198–210.
75.
BenbowAStewartMYeomanG.Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ2001; 322(7280): 236.
76.
NissenSE.The rise and fall of rosiglitazone. Eur Heart J2010; 31(7): 773–776.
77.
LiXSongDLengSX.Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment. Clin Interv Aging2015; 10: 549–560.
78.
HuynhKMartinsRNMeiklePJ.Lipidomic profiles in diabetes and dementia. J Alzheimers Dis2017; 59(2): 433–444.
79.
Rojas-GutierrezEMuñoz-ArenasGTreviñoS, et al. Alzheimer’s disease and metabolic syndrome: a link from oxidative stress and inflammation to neurodegeneration. Synapse2017; 71(10): e21990.
80.
Chin-HsiaoT.Metformin and the risk of dementia in type 2 diabetes patients. Aging Dis2019; 10(1): 37–48.
81.
HemmingsenBSchrollJBWetterslevJ, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open2014; 2(3): E162–E175.
82.
UmpierrezGTofé PovedanoSPérez ManghiF, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care2014; 37(8): 2168–2176.
83.
LaplanteMSabatiniDM.mTOR signaling in growth control and disease. Cell2012; 149(2): 274–293.
84.
Dalle PezzePRufSSonntagAG, et al. A systems study reveals concurrent activation of AMPK and mTOR by amino acids. Nat Commun2016; 7(1): 13254.
85.
DowlingRJZakikhaniMFantusIG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res2007; 67(22): 10804–10812.
86.
ViolletBGuigasBSanz GarciaN, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond)2012; 122(6): 253–270.
87.
DongJPengHYangX, et al. Metformin mediated microRNA-7 upregulation inhibits growth, migration, and invasion of non-small cell lung cancer A549 cells. Anticancer Drugs2020; 31(4): 345–352.
88.
HirschHAIliopoulosDStruhlK.Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A2013; 110(3): 972–977.
89.
Kanigur SultuybekGSoydasTYenmisG. NF-κB as the mediator of metformin’s effect on ageing and ageing-related diseases. Clin Exp Pharmacol Physiol2019; 46(5): 413–422.
90.
BodmerMBeckerCMeierC, et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol2012; 107(4): 620–626.
91.
DecensiAPuntoniMGoodwinP, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila)2010; 3(11): 1451–1461.
92.
LandmanGWKleefstraNvan HaterenKJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care2010; 33(2): 322–326.
93.
LibbyGDonnellyLADonnanPT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care2009; 32(9): 1620–1625.
94.
AlimovaINLiuBFanZ, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle2009; 8(6): 909–915.
95.
Vázquez-MartínAOliveras-FerrarosCdel BarcoS, et al. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol2009; 11(7): 455–459.
96.
Vazquez-MartinAOliveras-FerrarosCMenendezJA.The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle2009; 8(1): 88–96.
97.
ZhongTMenYLuL, et al. Metformin alters DNA methylation genome-wide via the H19/SAHH axis. Oncogene2017; 36(17): 2345–2354.
98.
MonamiMLamannaCBalziD, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol2009; 46(4): 279–284.
99.
NotoHGotoATsujimotoT, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One2012; 7(3): e33411.
100.
SorannaDScottiLZambonA, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist2012; 17(6): 813–822.
101.
ZhangZJZhengZJKanH, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care2011; 34(10): 2323–2328.
102.
LanBZhangJZhangP, et al. Metformin suppresses CRC growth by inducing apoptosis via ADORA1. Front Biosci (Landmark Ed)2017; 22(2): 248–257.
103.
WinkKCBelderbosJSDielemanEM, et al. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiother Oncol2016; 118(3): 453–459.
104.
MenaminÚCCardwellCRHughesCM, et al. Metformin use and survival from lung cancer: a population-based cohort study. Lung Cancer2016; 94: 35–39.
105.
YuHYinLJiangX, et al. Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS One2014; 9(12): e116327.
106.
MargelDUrbachDRLipscombeLL, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol2013; 31(25): 3069–3075.
107.
HadadSMHardieDGAppleyardV, et al. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol2014; 16(8): 746–752.
108.
CamachoLDasguptaAJiralerspongS.Metformin in breast cancer—an evolving mystery. Breast Cancer Res2015; 17(1): 88.
109.
Klubo-GwiezdzinskaJJensenKCostelloJ, et al. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer2012; 19(3): 447–456.
110.
LiuJLiMSongB, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol2013; 31(2): 264–270.
111.
LiYHuLXiaQ, et al. The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis. Int Urol Nephrol2017; 49(6): 975–981.
112.
CastleBTDockCHemmatM, et al. Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv2020: 2020.05.22.111237.
113.
KaramBSMorrisRSBramanteCT, et al. mTOR inhibition in COVID-19: a commentary and review of efficacy in RNA viruses. J Med Virol2021; 93(4): 1843–1846.
114.
Del CampoJAGarcía-ValdecasasMGil-GómezA, et al. Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PLoS One2018; 13(1): e0191805.
115.
GordonDEJangGMBouhaddouM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature2020; 583(7816): 459–468.
116.
NakashimaKTakeuchiKChiharaK, et al. Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways. Microbiol Immunol2011; 55(11): 774–782.
117.
BramanteCTBuseJTamaritzL, et al. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. J Med Virol2021; 93(7): 4273–4279.
118.
BramanteCTIngrahamNEMurrayTA, et al. Metformin and risk of mortality in patients hospitalized with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev2021; 2(1): e34–e41.
119.
CariouBHadjadjSWargnyM, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia2020; 63(8): 1500–1515.
120.
CrouseABGrimesTLiP, et al. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front Endocrinol (Lausanne)2020; 11: 600439.
121.
LiYYangXYanP, et al. Metformin in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne)2021; 8: 704666.
122.
LuoPQiuLLiuY, et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg2020; 103(1): 69–72.
123.
PostlerTSPengVBhattDM, et al. Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism. Scient Rep2021; 11(1): 18721.
124.
XinGWeiZJiC, et al. Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release. Sci Rep2016; 6: 36222.
